非酒精性脂肪肝的药物治疗进展

Progress in drug treatment of nonalcoholic fatty liver disease

非酒精性脂肪肝(NAFLD)已逐渐成为我国第一大肝病,其危害不仅可进展为非酒精性脂肪性肝炎(NASH)、肝硬化、肝细胞癌,而且作为代谢综合征(MS)的重要组分与心脑血管疾病密切相关,日益受到相关学科研究者的重视。NAFLD的治疗除了肝病本身,也应包括患者可能并存的异常代谢组分如肥胖、高脂血症、胰岛素抵抗(IR)、2型糖尿病(T2DM)等。NAFLD的治疗包括非药物治疗——生活方式改变、药物治疗两方面,前者为治疗NAFLD的基础。目前治疗NAFLD的药物主要包括胰岛素增敏剂、抗氧化剂、微生态制剂、降脂药、减肥药、保肝抗炎药物及中药。

Nonalcoholic fatty liver disease （NAFLD） is becoming the largest liver disease in China, and it has attracted more and more attention by bringing about not only liver disease, such as NASH, cirrhosis, hepatic carcinoma, but also cardiovascular and cercbrovascular diseases. So the therapy should take into account consideration not only NAFLD, but also other components of MS such as obesity, hyperlipidaemia, insulin resistance （IR）, type 2 diabetes （T2DM）, and so on. The therapy should include two sides, non-drug treatment-lifestyle modification, and drug treatment, and the former is basic treatment. Current drugs for treating NAFLD mainly include euglycemic agent, antioxidant, microecologics, descendens blood fat drugs, protecting liver function drugs, and traditional Chinese medicine.